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Q  What is the most effective 
treatment for scabies?
 Topical permethrin is the most 
 effective treatment for classic sca-
bies (strength of recommendation [SOR]: 
A, meta-analyses with consistent results). 
Topical lindane and crotamiton are in-
ferior to permethrin but appear equivalent 
to each other and benzyl benzoate, sulfur, 
and natural synergized pyrethrins (SOR: B, 
limited randomized trials). 
Although not as effective as topical 
permethrin, oral ivermectin is an effective 
treatment compared with placebo (SOR: B, 
a single small randomized trial). 
Oral ivermectin may reduce the preva-
lence of scabies at one year in populations 
with endemic disease more than topical 
permethrin (SOR: B, a single randomized 
trial).
ONLINE
EXCLUSIVE
Evidence summary 
A 2007 Cochrane review on scabies treatment 
identified 11 trials that evaluated permethrin 
for treating scabies.1 In 2 trials, 140 patients 
were randomized to receive either 200 mcg/kg 
of oral ivermectin or overnight application of 
5% topical permethrin. Topical permethrin 
was superior to oral ivermectin with failure 
rates at 2 weeks of 8% and 39%, respectively 
(number needed to treat [NNT]=4; risk ratio 
[RR]=4.61; 95% confidence interval [CI], 2.07-
10.26). 
Two trials compared 5% topical per-
methrin with 10% topical crotamiton in 
194 patients with follow-up at 28 days. Per-
methrin was superior to crotamiton with fail-
ure rates of 6% and 26%, respectively (NNT=6; 
RR=0.24; 95% CI, 0.10-0.55). 
Five trials with 753 patients compared 
topical permethrin, 2.5% to 3.5%, with topi-
cal 1% lindane, but heterogeneity precluded 
pooling all the studies. In the 3 studies 
(554 patients) that were comparable, topi-
cal 3.5% permethrin was superior to lindane 
after a single application of each with failure 
rates of 9% and 15%, respectively (NNT=17; 
RR=0.59; 95% CI, 0.37-0.95). 
Two trials that compared permethrin 
with topical benzyl benzoate (53 patients) 
and natural synergized pyrethrins (40 pa-
tients) showed no difference in treatment 
failures, but the trials were small and lacked 
sufficient statistical power. 
Four additional studies included in 
the review compared crotamiton with lin-
dane (100 patients), lindane with sulfur 
(68 patients), benzyl benzoate with sulfur 
(158 patients), and benzyl benzoate with 
natural synergized pyrethrins (240 patients). 
None demonstrated superiority, but all 
were small studies.1 A single small trial of 
55 patients that compared oral ivermectin 
200 mcg/kg with placebo showed failure rates 
at one week of 21% and 85%, respectively 
(NNT=2; RR=0.24; 95% CI, 0.12-0.51).1 
Topical permethrin  
vs oral ivermectin
A 2014 systematic review of 5 studies included 
2 new studies done after the 2007 Cochrane 
review.2 The new RCTs compared a single 
application of 5% topical permethrin with a 
single dose or 2 doses of oral ivermectin given 
2 weeks apart. No statistically significant dif-
ferences were found in these studies.2 Both 
underpowered studies favored topical per-
methrin, however. 
The P value was .42 in one study of 
242 adults and children, and this trial showed 
a clinical cure rate at 2 weeks of 93% us-
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The CDC and 
the European 
Guideline for the 
Management 
of Scabies both 
recommend  
topical  
permethrin  
as first-line 
therapy for  
classical scabies.
ing topical permethrin vs 86% using oral 
ivermectin.2 
The other study of 120 adults and chil-
dren didn’t report a P value or identify statis-
tically significant differences between topical 
permethrin and oral ivermectin.2 This study 
reported a clinical cure rate of 87% with topi-
cal permethrin, 78% with a single dose of oral 
ivermectin, and 67% with 2 doses of oral iver-
mectin 2 weeks apart.2 
Ivermectin may control endemic scabies  
better than permethrin
A 2015 randomized controlled trial with 
2051 patients compared mass treatments 
in a scabies-endemic population in Fiji.3 
The trial had 3 arms: a standard-care group 
treated with 5% topical permethrin if symp-
toms were present and retreated at 2 weeks 
if symptoms persisted; a permethrin group 
in which all participants, whether infected 
or not, received 5% permethrin followed by a 
second dose at 7 to 14 days if symptoms per-
sisted; and an oral ivermectin group in which 
participants were treated with 200 mcg/kg, 
repeated in 7 to 14 days for those with base-
line scabies. 
At 12 months, the relative risk reductions 
were 94% (95% CI, 83%-100% for the ivermec-
tin group, 62% (95% CI, 49%-75%) for the per-
methrin group, and 49% (95% CI, 37%-60%) 
for the standard-care group.3 The study had 
multiple limitations, and all groups were per-
mitted to receive standard care at any time 
during the 12-month follow-up period. Nev-
ertheless, the findings suggest that endemic 
scabies control with ivermectin may be supe-
rior to topical permethrin.
Recommendations
The Centers for Disease Control and Preven-
tion (CDC)4 and the European Guideline for 
the Management of Scabies5 both recommend 
topical permethrin as first-line therapy for 
classical scabies and note that oral ivermec-
tin may be safe and effective but isn’t licensed 
for scabies treatment in most countries. Iver-
mectin isn’t approved by the United States 
Food and Drug Administration for treating 
scabies.
The CDC recommendations note that 
the safety of ivermectin in children weighing 
less than 15 kg and pregnant women hasn’t 
been established.4                             JFP
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